Dec 6, 2018
Moffitt Cancer Center: Ports: Overview and Placement
Moffitt Cancer Center: Ports: Overview and Placement
162
Dec 5, 2018
Myeloma Canada: Patient Handbook - Clinical Trials as a Treatment Option
Myeloma Canada: Patient Handbook - Clinical Trials as a Treatment Option https://myeloma.ca/pixms/uploads/serve/ckeditor/clinical_trials_...
66
Dec 5, 2018
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
Multiple Myeloma Research Consortium phase 2 study Dara-KRd NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose...
200
Dec 5, 2018
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) This study will test the safety...
130
Dec 4, 2018
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2
DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...
372
Dec 4, 2018
NCT03763370: Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Myeloma
NCT03763370: Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma NCT03763370: Expanded Access...
26
Dec 4, 2018
IMF - International Myeloma Foundation: Concise Review of the Disease and Treatment Options
IMF - International Myeloma Foundation: Concise Review of the Disease and Treatment Options https://imf-d8-prod.s3.us-west-1.wasabisys.co...
236
Dec 4, 2018
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01) Sponsor Trillium Therapeutics...
536
Dec 4, 2018
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in RRMM Myeloma
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Study of...
48
Dec 3, 2018
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss) FiTNEss (UK-MRA...
352
Dec 2, 2018
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Study of...
111
Dec 1, 2018
NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222: Phase 2: SELIBORDARA:...
35